Eterna Therapeutics

ERNA37

Penny Stock

$0.73arrow_drop_down12.57%-$0.10

Penny Stock

ERNA37

$0.73

arrow_drop_down12.57%-$0.10

Penny Stock

Performance History

Key Stats
Open	$0.91
Prev. Close	$0.94
EPS	-4.43
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$42.88M
PE Ratio	-

	LOW	HIGH
Day Range	0.83	1.44
52 Week Range	0.83	2.63

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-4.43

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc., also known by its ticker symbol ERNA, is a biotechnology company that focuses on the development and commercialization of innovative therapies for various diseases. The company is dedicated to advancing the field of precision medicine and personalized therapeutics to improve patient outcomes. With a strong team of scientists and researchers, Eterna Therapeutics Inc. is at the forefront of cutting-edge research and development in the biotechnology industry.

The stock price history of Eterna Therapeutics Inc. (ERNA) reflects the company's growth and potential. Over the years, the stock has shown a steady increase in value, with occasional fluctuations in response to market conditions and industry dynamics. Investors who have been tracking ERNA stock have witnessed its promising performance and have taken positions in anticipation of future growth.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Matthew Angel Ph.D.
Headquarters: Cambridge
Employees: 9
Exchange: NASDAQ

Keep an eye on Eterna Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Eterna Therapeutics's (ERNA) price per share?

The current price per share for Eterna Therapeutics (ERNA) is $0.73. The stock has seen a price change of -$0.1 recently, indicating a -12.57% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Eterna Therapeutics (ERNA)?

For Eterna Therapeutics (ERNA), the 52-week high is $2.63, which is 260.27% from the current price. The 52-week low is $0.65, the current price is 12.48% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Eterna Therapeutics (ERNA) a growth stock?

Eterna Therapeutics (ERNA) has shown an average price growth of -6.8% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eterna Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Eterna Therapeutics (ERNA) stock price performance year to date (YTD)?

As of the latest data, Eterna Therapeutics (ERNA) has a year-to-date price change of -61.17%. Over the past month, the stock has experienced a price change of -31.78%. Over the last three months, the change has been -58.29%. Over the past six months, the figure is -63.5%.

help

Is Eterna Therapeutics (ERNA) a profitable company?

Eterna Therapeutics (ERNA) has a net income of -$21.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -10.49K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$21.14M. Furthermore, the EBITDA is -$21.86M.

help

What is the market capitalization of Eterna Therapeutics (ERNA)?

Eterna Therapeutics (ERNA) has a market capitalization of $42.88M. The average daily trading volume is 0.72, indicating the stock's liquidity and investor engagement.

News

CALENDAR OF EVENTS

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

May 10, 2024

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

DIRECTORS AND OFFICERS

May 8, 2024

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

DIRECTORS AND OFFICERS

Feb 20, 2024

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

HEALTH

STOCK MARKET NEWS

Jan 3, 2024

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

DIRECTORS AND OFFICERS

Dec 20, 2023